Correction to: A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression by Nayak, et al. Psychedelic Med 2023;1(1):18-26; doi: 10.1089/psymed.2022.0002.
[This corrects the article DOI: 10.1089/psymed.2022.0002.].
Bibliographic context
- Journal
- Unknown
- Date
- 2024-12-01
- Source
- Europe PMC
- PubMed
- 40045987
Topics and keywords
Citation graph
0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.
Related papers
Contribution of the Serotonin 5-HT2A Receptor to the Therapeutic Effect of Psilocin on Social Behavior Deficits in Mice Repeatedly Exposed to Social Defeat StressNeuropsychopharmacology Reports · 2026-08-31Trajectories of psychedelic-assisted change: An observational study of a psilocybin retreat program followed by psychotherapeutic interventionsJournal of Psychedelic Studies · 2026-07-02Past-Year Psilocybin and Alcohol Co-Use: Associations With Mental Health SymptomsJournal of Drug Issues · 2026-06-30Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive SymptomsClinicalTrials.gov · 2026-06-30Modeled Long-Term Effects of Psilocybin on Dynamic Activity and Effective Connectivity of Fronto-Striatal-Thalamic Circuits.Human Brain Mapping · 2026-06-30MFCC-DFT mapping of ligand recognition at the 5-HT2A receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.Unknown journal · 2026-06-30Psilocybin as a novel treatment for chronic pain.British journal of pharmacology · 2026-06-30The Australia story: Current status and future challenges for the clinical applications of psychedelics.British journal of pharmacology · 2026-06-30